BAY1082439
Based on 1 publication(s) in Google Scholar
BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.35%
- CAS 番号: 1375469-38-7
- 分子式: C25H30N6O5
- 分子量:494.54
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-B0215
AcetylcysteineMucolytic Agent -
HY-15244
AlpelisibPI3Kα Inhibitor -
HY-101562
InavolisibPI3Kα Inhibitor -
HY-101272
GDC-0326PI3Kα Inhibitor -
HY-100886R
BAY1082439 (Standard)PI3Kα/β/δ Inhibitor -
HY-12285
Serabelisibp110α Inhibitor -
HY-70063
BuparlisibPI3K Inhibitor -
HY-50094
PictilisibPI3Kα/δ Inhibitor -
HY-107834
PIK-75DNA-PK/p110α Inhibitor -
HY-50847
ZSTK474Autophagy Inducer -
HY-10344
AZD 6482PI3Kβ Inhibitor -
HY-12036
GSK1059615Apoptosis Inducer
MedChemExpress（MCE）の使用を引用している文献 BAY1082439
More
生物活性
製品説明
IC50 & Target
[1]|
PI3Kα |
PI3Kβ |
PI3Kδ |
体外実験
BAY1082439 is a highly selective PI3Kα/α-balanced inhibitor. BAY1082439 has an IC50 ratio of 1:3 in biochemical assays of PI3Kα (4.9 nM) vs. PI3Kα (15.0 nM), and >1000-fold selectivity against mTOR kinase[1].
BAY1082439 (0.1-1 μM; 72 hours) is more effective than PI3Kα- and/or PI3Kβ-selective inhibitors in blocking PTEN-null prostate cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:PC3 and LNCaP cells (PTEN-null human prostate cancer cell lines)
-
Concentration:0.1, 0.33, 1, 3.3, 10 μM
-
Incubation Time:72 hours
-
Result:Efectively inhibited cell growth by blocking the G1/S cell cycle transition and by inducing apoptosis.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pten conditional knockout mouse model (Pb-Cre+;PtenL/L, CP model)[2]
-
Dosage:75 mg/kg
-
Administration:P.o.; daily for 4 weeks
-
Result:Significantly decreased tumor size and P-AKT staining, nearly normal luminal architecture, and a significant reduction of Ki67-positive cells. Significantly inhibit the human prostate cancer growth.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1375469-38-7
-
性状 Solid
-
分子量 494.54
-
分子式 C25H30N6O5
-
Color White to off-white
-
SMILES
O=C(C1=CC=CN=C1C)NC2=NC3=C(C=CC(OC[C@H](O)CN4CCOCC4)=C3OC)C5=NCCN25
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
溶剤 & 溶解度
体外:
0.1 M HCl : 16.67 mg/mL (33.71 mM; ultrasonic and warming and heat to 60°C)
DMSO : 5 mg/mL (10.11 mM; ultrasonic and adjust pH to 5 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 25 mg/mL (50.55 mM); Suspended solution; Need ultrasonic
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.1 M HCl | 1 mM | 2.0221 mL | 10.1104 mL | 20.2208 mL | 50.5520 mL |
| 5 mM | 0.4044 mL | 2.0221 mL | 4.0442 mL | 10.1104 mL | |
| 10 mM | 0.2022 mL | 1.0110 mL | 2.0221 mL | 5.0552 mL | |
| 0.1 M HCl | 15 mM | 0.1348 mL | 0.6740 mL | 1.3481 mL | 3.3701 mL |
| 20 mM | 0.1011 mL | 0.5055 mL | 1.0110 mL | 2.5276 mL | |
| 25 mM | 0.0809 mL | 0.4044 mL | 0.8088 mL | 2.0221 mL | |
| 30 mM | 0.0674 mL | 0.3370 mL | 0.6740 mL | 1.6851 mL |
BAY1082439 関連分類
HY-100886 関連分類
Powered by Bioz